Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection. The regulatory clearance covers two strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. This approval allows the company to commercialize a generic version of the reference listed drug (RLD), BRIDION® Injection, manufactured by Merck Sharp & Dohme LLC. The product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.

According to data from IQVIA, the Sugammadex product category generated US sales of approximately USD 1.6 billion for the twelve months ending April 2026. Gland Pharma has successfully launched the product on Day 1 through its designated marketing partner, positioning itself to capture market share in this high-value therapeutic segment immediately upon approval.

Product Details

The approved formulation is described as bioequivalent and therapeutically equivalent to the RLD. The specific configurations approved by the USFDA are outlined below:

Regulatory Disclosure

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The press release was issued on July 29, 2026, and signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer.

Market Significance

The immediate launch of the product highlights Gland Pharma's operational readiness in the sterile injectables segment. By entering a market with USD 1.6 billion in recent annual sales, the company targets a significant revenue stream without the delay typically associated with post-approval supply chain ramp-ups. The reliance on a marketing partner for Day 1 launch reflects a strategic focus on manufacturing efficiency while leveraging external networks for distribution, a model consistent with its broader business-to-business (B2B) approach in global markets.

Gland Pharma witnessed a notable block trade on the National Stock Exchange (NSE), with the transaction valued at ₹51.59 crores. The deal involved approximately 209,098 shares changing hands at a price of ₹2467.40 per share.

Block Trade Details

The following table summarizes the key parameters of the block trade recorded on the NSE:

Block trades of this scale typically involve institutional participants and are executed outside the regular order book to minimize market impact. The transaction in Gland Pharma's shares reflects notable activity in the counter at the stated price level.